Bayer joins the COVID-19 vaccine push, backing CureVac shotShortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to Share XBayer joins the COVID-19 vaccine push, backing CureVac shothttps://pharmaphorum.com/news/bayer-joins-the-covid-19-vaccine-push-backing-curevacs-shot/
Amgen hands off leprosy, TB candidate to Australian non-profitAmgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Share XAmgen hands off leprosy, TB candidate to Australian non-profithttps://pharmaphorum.com/news/amgen-hands-off-leprosy-tb-candidate-to-australian-non-profit/
Merck cuts $1bn deal with Janux for cancer T-cell therapiesIn a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Share XMerck cuts $1bn deal with Janux for cancer T-cell therapieshttps://pharmaphorum.com/news/merck-cuts-1bn-deal-with-janux-for-cancer-t-cell-therapies/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
AZ buys oral PCSK9 cholesterol drug from Dogma TherapeuticsAstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share XAZ buys oral PCSK9 cholesterol drug from Dogma Therapeuticshttps://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Exelixis doubles down on ADCs for cancer with NBE, Catalent dealsExelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug Share XExelixis doubles down on ADCs for cancer with NBE, Catalent dealshttps://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/
AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drugAbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record Share XAbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drughttps://pharmaphorum.com/news/abbvie-signs-2-9bn-deal-with-i-mab-for-dont-eat-me-cancer-drug/
Latecomer Lilly throws cash at Innovent PD-1 partnershipEli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights Share XLatecomer Lilly throws cash at Innovent PD-1 partnershiphttps://pharmaphorum.com/news/latecomer-lilly-throws-cash-at-innovent-pd-1-partnership/